Ipsen Puts Up $1.6B To Absorb ImCheck for Mid-Stage Leukemia Antibody

The deal focuses on ICT01, a monoclonal antibody being tested in acute myeloid leukemia. ImCheck is also developing assets in infectious disease and other oncology indications.

Scroll to Top